全文获取类型
收费全文 | 967369篇 |
免费 | 80637篇 |
国内免费 | 6132篇 |
专业分类
耳鼻咽喉 | 13934篇 |
儿科学 | 27432篇 |
妇产科学 | 26397篇 |
基础医学 | 132370篇 |
口腔科学 | 27044篇 |
临床医学 | 90432篇 |
内科学 | 176148篇 |
皮肤病学 | 18203篇 |
神经病学 | 74921篇 |
特种医学 | 38837篇 |
外国民族医学 | 172篇 |
外科学 | 145694篇 |
综合类 | 45841篇 |
现状与发展 | 33篇 |
一般理论 | 310篇 |
预防医学 | 79838篇 |
眼科学 | 21874篇 |
药学 | 75486篇 |
104篇 | |
中国医学 | 8215篇 |
肿瘤学 | 50853篇 |
出版年
2021年 | 8337篇 |
2018年 | 9657篇 |
2017年 | 8284篇 |
2016年 | 8623篇 |
2015年 | 11034篇 |
2014年 | 15688篇 |
2013年 | 23127篇 |
2012年 | 32141篇 |
2011年 | 33696篇 |
2010年 | 21859篇 |
2009年 | 20475篇 |
2008年 | 31279篇 |
2007年 | 33284篇 |
2006年 | 32377篇 |
2005年 | 30998篇 |
2004年 | 29128篇 |
2003年 | 27539篇 |
2002年 | 25934篇 |
2001年 | 38096篇 |
2000年 | 38144篇 |
1999年 | 31684篇 |
1998年 | 9733篇 |
1997年 | 8970篇 |
1996年 | 8834篇 |
1995年 | 8268篇 |
1992年 | 26766篇 |
1991年 | 26232篇 |
1990年 | 25705篇 |
1989年 | 24765篇 |
1988年 | 23290篇 |
1987年 | 22945篇 |
1986年 | 21819篇 |
1985年 | 21171篇 |
1984年 | 16453篇 |
1983年 | 14031篇 |
1982年 | 8914篇 |
1981年 | 8251篇 |
1979年 | 16729篇 |
1978年 | 12101篇 |
1977年 | 10167篇 |
1976年 | 9310篇 |
1975年 | 10129篇 |
1974年 | 12628篇 |
1973年 | 12124篇 |
1972年 | 11535篇 |
1971年 | 10672篇 |
1970年 | 10201篇 |
1969年 | 9900篇 |
1968年 | 8893篇 |
1967年 | 8215篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
32.
Samir Gupta MD MDCS AGAF Balambal Bharti MBBS MPH PhD Dennis J. Ahnen MD Daniel D. Buchanan PhD Iona C. Cheng PhD MPH Michelle Cotterchio PhD Jane C. Figueiredo PhD Steven J. Gallinger MD MSc Robert W. Haile DrPH MPH Mark A. Jenkins PhD Noralane M. Lindor MD Finlay A. Macrae MD AGAF Loïc Le Marchand MD PhD Polly A. Newcomb PhD MPH Stephen N. Thibodeau PhD Aung Ko Win MBBS MPH PhD Maria Elena Martinez PhD 《Cancer》2020,126(13):3013-3020
33.
目的探讨疱疹病毒抗体阳性的肺炎支原体肺炎(MPP)患儿免疫状况及临床特征。方法回顾分析2015年1月—2017年5月收治的360例2个月~16岁因MPP住院的患儿临床资料,以EB病毒(EBV)、巨细胞病毒(CMV)、单纯疱疹病毒(HSV)任一疱疹病毒IgM抗体阳性的162例患儿为抗体阳性组,另198例EBV、CMV、HSV抗体均阴性的患儿作为对照组,两组进行分析比较。结果 360例MPP患儿中男188例、女172例,合并疱疹病毒IgM抗体阳性162例,其中EBV IgM阳性97例,阳性率26.9%;CMV IgM阳性39例,阳性率10.8%;HSV IgM阳性97例,阳性率26.9%。所有患儿均未予抗病毒治疗,经治疗症状缓解好转出院。抗体阳性组重症MPP、大叶性实变、并发呼吸衰竭的比例均高于对照组,血清IgM、CD~(4+)T细胞、CD~(8+)T细胞、淋巴细胞、NK细胞、白细胞计数、乳酸脱氢酶、丙氨酸氨基转移酶均高于对照组,大环内酯类抗生素使用时间长于对照组,使用激素率高于对照组,差异均有统计学意义(P均0.05)。MPP合并2种病毒IgM抗体阳性者的血IgM和三酰甘油水平高于合并1种者,差异有统计学意义(P0.05)。合并3种病毒IgM抗体阳性者与合并1种者比较,住院时间、发热时间、大环内酯类抗生素使用时间均有延长,血IgM、丙氨酸氨基转移酶水平更高,重症MPP发生率增高,差异均有统计学意义(P0.05)。结论疱疹病毒IgM抗体阳性MPP患儿的炎症反应强烈,临床症状重,病程长,并发症多,需更长时间的治疗。 相似文献
34.
Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population 下载免费PDF全文
Partha S RoyTomar NyoduMunlima HazarikaB J SaikiaC BhuyanAmit InamdarC W NyutheB BorthakurJ D Sharma 《Asian Pacific journal of cancer prevention》2019,20(4):1139-1145
Objective: Human epidermal growth factor receptor 2 (erbb2/HER2) overexpression, has now been implicatedin advanced gastric and gastroesophageal junction cancers. The study was conducted to determine the rate of HER2positivity in patients with locally advanced or metastatic gastric and gastroesophageal adenocarcinoma in North-EastIndia and to assess the impact of various demographic and clinical parameters on HER2 positivity. Methods: A total of68 patients of age >18 years of gastric and gastroesophageal adenocarcinoma diagnosed on histopathological examinationfrom September 2016 to February 2018 at Dr B Borooah Cancer Institute, Assam were enrolled for the observational(epidemiological) study. All patients were subjected to the HER2 immunohistochemistry test using a FDA-approved,standardized test kit. HER2 expression was correlated with various demographic and clinicopathological parameters.Results: The overall rate of HER2 positivity in the population studied was 56% (n=38). The rate was non-significantlyhigher in male, older age group (>60 years) and Hindu population. Similarly, HER2 positivity rate was higher in patientswith well differentiated histology and was more common in patients with stage II and III diseases, but neither of theassociations is statistically significant. HER2 positivity rate was significantly higher in proximal and in GEJ tumours(56% versus 44%, P=0.002). Conclusion: HER2 overexpression was evident in 56% of the North-East Indian patientswith locally advanced and metastatic gastric and gastroesophageal adenocarcinoma. The overexpression correlatedsignificantly with primary tumour site. Routine testing of gastric and gastroesophageal tumours for HER2 expressionis recommended to provide a therapeutic advantage in Indian patients. 相似文献
35.
36.
近年来,蚊虫传播的黄热病在非洲和南美洲地区大面积“再流行”,仅南美洲的巴西在一年时间就发现数千例黄热病确诊病例,黄热病已经在非洲和南美洲地区造成巨大的公共卫生负担。此外,在黄热病非流行国家和地区发现大量输入性病例,使得黄热病有可能在非洲和南美洲以外的地区成为“新发传染病”而在世界更大范围流行。为此,世界卫生组织制定了“消除黄热病流行(EYE)”战略,预计利用10年时间在黄热病流行地区接种13.8亿剂量黄热疫苗,以降低黄热病对国际公共卫生健康的危害。 相似文献
37.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献38.
39.
40.
Autoimmune comorbid diseases associated with lichen planus: a nationwide case–control study 下载免费PDF全文